Period Ending | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2020 | |
|---|---|---|---|---|
Total Revenue | 2,231 | -- | 0 | |
Cost of Revenue | -- | -- | -- | |
Gross Profit | 2,231 | -- | -- | |
Operating Expenses | ||||
Research Development | 7,587 | -- | -- | |
Selling General and Administrative | 5,374 | -- | -- | |
Non Recurring | -- | -- | -- | |
Others | (13) | -- | 1,369 | |
Total Operating Expenses | 12,949 | -- | 1,369 | |
Operating Income or Loss | (10,718) | -- | (1,369) | |
Income from Continuing Operations | ||||
Total Other Income/Expenses Net | (446) | -- | 3,298 | |
Earnings Before Interest And Taxes | (10,285) | -- | (1,369) | |
Interest Expense | -- | -- | -- | |
Income Before Tax | (10,639) | -- | 2,649 | |
Income Tax Expense | (77) | -- | 244 | |
Minority Interest | (328) | -- | -- | |
Net Income From Continuing Ops | (10,626) | -- | 2,405 | |
Non-recurring Events | ||||
Discontinued Operations | -- | -- | -- | |
Extraordinary Items | -- | -- | -- | |
Effect Of Accounting Changes | -- | -- | -- | |
Other Items | 0 | -- | 0 | |
Net Income | (10,626) | -- | 2,405 | |
Preferred Stock And Other Adjustments | -- | -- | -- | |
Net Income Applicable To Common Shares | (10,626) | -- | 2,403 | |